The findings of a higher rate of severe disease, hospitalization, and mortality among patients with SARS-CoV-2 infection and the confirmation of a high expression of ACE-2 in the cardiac tissue have fuelled the interest in the routine assessment of cardiac damage in patients evaluated for COVID-19. Here, ACE2 is linked to COVID-19.